Valuation Edwards Lifesciences Corporation
Stocks
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 92.21 USD | +0.96% |
|
-2.29% | +8.16% |
| 04:06pm | RBC Raises Price Target on Edwards Lifesciences to $110 From $100, Keeps Outperform Rating | MT |
| 07-08 | Citigroup Adjusts Edwards Lifesciences Price Target to $110 From $101 | MT |
Company Valuation: Edwards Lifesciences Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 80,883 | 46,128 | 46,246 | 43,663 | 49,471 | 53,095 | - | - |
| Change | - | -42.97% | 0.25% | -5.58% | 13.3% | 7.33% | - | - |
| Enterprise Value (EV) 1 | 80,616 | 45,956 | 45,198 | 40,285 | 45,843 | 49,612 | 48,022 | 46,179 |
| Change | - | -42.99% | -1.65% | -10.87% | 13.8% | 8.22% | -3.21% | -3.84% |
| P/E | 54.4x | 30.6x | 33.2x | 10.6x | 46.6x | 32.9x | 28.2x | 25.1x |
| PBR | 13.9x | 7.82x | 6.99x | 4.36x | 4.79x | 4.85x | 4.41x | 4.21x |
| PEG | - | 12.14x | -5.79x | 0x | -0.6x | 0.6x | 1.7x | 2.1x |
| Capitalization / Revenue | 15.5x | 8.57x | 7.7x | 8.03x | 8.15x | 7.87x | 7.16x | 6.52x |
| EV / Revenue | 15.4x | 8.54x | 7.53x | 7.41x | 7.56x | 7.35x | 6.48x | 5.67x |
| EV / EBITDA | 46.6x | 23.7x | 24.1x | 24.1x | 25.5x | 23.4x | 20.2x | 17.2x |
| EV / EBIT | 50.6x | 25.6x | 26.1x | 26.6x | 27.9x | 25.3x | 21.9x | 18.7x |
| EV / FCF | 57.3x | 47.2x | 47.9x | 139x | 34.3x | 36.4x | 28.3x | 23.9x |
| FCF Yield | 1.74% | 2.12% | 2.09% | 0.72% | 2.91% | 2.75% | 3.53% | 4.19% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 2.38 | 2.44 | 2.3 | 6.97 | 1.83 | 2.804 | 3.273 | 3.671 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 5,232 | 5,382 | 6,005 | 5,440 | 6,068 | 6,748 | 7,411 | 8,146 |
| EBITDA 1 | 1,729 | 1,936 | 1,879 | 1,670 | 1,800 | 2,122 | 2,372 | 2,682 |
| EBIT 1 | 1,594 | 1,796 | 1,734 | 1,514 | 1,644 | 1,959 | 2,195 | 2,466 |
| Net income 1 | 1,503 | 1,522 | 1,402 | 4,175 | 1,074 | 1,624 | 1,891 | 2,115 |
| Net Debt 1 | -267 | -172.7 | -1,048 | -3,378 | -3,628 | -3,482 | -5,073 | -6,915 |
| Reference price 2 | 129.55 | 74.61 | 76.25 | 74.03 | 85.25 | 92.21 | 92.21 | 92.21 |
| Nbr of stocks (in thousands) | 624,334 | 618,260 | 606,500 | 589,800 | 580,300 | 575,800 | - | - |
| Announcement Date | 26/01/22 | 31/01/23 | 06/02/24 | 11/02/25 | 10/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.88x | 7.35x | 23.38x | -.--% | 53.09B | |
| 26.39x | 4.75x | 18.29x | 0.35% | 196B | |
| 44.98x | 11.7x | 26.18x | -.--% | 144B | |
| 32.21x | - | - | 0.72% | 141B | |
| 16.45x | 3.42x | 11x | -.--% | 66.54B | |
| 18.34x | 2.12x | 10.96x | 2.86% | 44.12B | |
| 26.09x | 5.2x | 17.77x | 0.76% | 37.93B | |
| 45.62x | 6.37x | 19.56x | -.--% | 36.96B | |
| 14.53x | 1.62x | 9.08x | 0.24% | 29.43B | |
| 19.26x | 5.05x | 13.03x | 1.19% | 29.41B | |
| Average | 27.68x | 5.29x | 16.58x | 0.61% | 77.83B | |
| Weighted average by Cap. | 30.20x | 6.21x | 18.60x | 0.47% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- EW Stock
- Valuation Edwards Lifesciences Corporation
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
